DoH Policies screened during the period: 1 January 2022 -31 March 2022
Date published:
In fulfilling its obligations under Section 75 the Department is required to equality screen all of its policies and services under consideration to determine whether they should be subject to a full equality impact.
Documents
- NICE Technology Appraisal TA752 - Belimumab for treating active autoantibody-positive systemic lupus erythematosus (review of TA397) (PDF 514KB)
- NICE Technology Appraisal TA753 - Cenobamate for treating focal onset seizures in epilepsy (PDF 513KB)
- NICE Technology Appraisal TA754 - Mogamulizumab for previously treated mycosis fungoides and Sézary syndrome (PDF 513KB)
- NICE Technology Appraisal TA755 - Risdiplam for treating spinal muscular atrophy (PDF 511B)
- NICE Technology Appraisal TA756 - Fedratinib for treating disease-related splenomegaly or symptoms in myelofibrosis (PDF 512KB)
- NICE Clinical Guideline NG201 - Antenatal care (updates and replaces CG62) (PDF 668KB)
- NICE Clinical Guideline NG204 - Babies, children and young people's experience of healthcare (PDF 515KB)
- NICE Clinical Guideline NG206 - Myalgic encephalomyelitis (or encephalopathy)/chronic fatigue syndrome: diagnosis and management (updates and replaces CG53) (PDF 514KB)
- NICE Clinical Guideline NG207 - Inducing labour (updates and replaces CG70) (PDF 558KB)
- NICE Technology Appraisal TA757 - Cabotegravir with rilpivirine for treating HIV-1 (PDF 513KB)
- NICE Technology Appraisal TA758 - Solriamfetol for treating excessive daytime sleepiness caused by narcolepsy (PDF 512KB)
- NICE Technology Appraisal TA759 - Fostamatinib for treating refractory chronic immune thrombocytopenia (PDF 509KB)
- NICE Clinical Guideline NG208 - Heart valve disease presenting in adults: investigation and management (partially updates and replaces CG187) (PDF 513KB)
- NICE Technology Appraisal TA760 - Selpercatinib for previously treated RET fusion-positive advanced non-small-cell lung cancer (PDF 510KB)
- NICE Technology Appraisal TA761 - Osimertinib for adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection (PDF 622KB)
- NICE Clinical Guideline NG210 - Pelvic floor dysfunction: prevention and non-surgical management (PDF 517KB)
- NICE Technology Appraisal TA764 - Fremanezumab for preventing migraine (rapid review of TA631) (PDF 512KB)
- NICE Technology Appraisal TA763 - Daratumumab in combination for untreated multiple myeloma when a stem cell transplant is suitable (PDF 512KB)
- NICE Technology Appraisal TA765 - Venetoclax with azacitidine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable (PDF 512KB)
- NICE Technology Appraisal TA766 - Pembrolizumab for adjuvant treatment of completely resected stage 3 melanoma (review of TA553) (PDF 512KB)
- NICE Technology Appraisal TA767 - Ponesimod for treating relapsing–remitting multiple sclerosis (PDF 512KB)
- NICE Technology Appraisal TA768 - Upadacitinib for treating active psoriatic arthritis after inadequate response to DMARDs (PDF 514KB)
- NICE Technology Appraisal TA769 - Palforzia for treating peanut allergy in children and young people (PDF 513KB)
- NICE Technology Appraisal TA770 - Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancer (review of TA600) (PDF 513KB)
- NICE Technology Appraisal TA772 - Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma after stem cell transplant or at least 2 previous therapies (PDF 514KB)
- NICE Technology Appraisal TA773 - Empagliflozin for treating chronic heart failure with reduced ejection fraction (PDF 514KB)
- NICE Technology Appraisal TA775 - Dapagliflozin for treating chronic kidney disease (PDF 557KB)
- NICE Technology Appraisal TA776 - Pitolisant hydrochloride for treating excessive daytime sleepiness caused by obstructive sleep apnoea (PDF 512KB)
- NICE Technology Appraisal TA777 - Solriamfetol for treating excessive daytime sleepiness caused by obstructive sleep apnoea (PDF 513KB)
- NICE Technology Appraisal TA778 - Pegcetacoplan for treating paroxysmal nocturnal haemoglobinuria (PDF 514KB)
- Northern Ireland Marketing MHRA Authorisation Route (NIMAR) (PDF 937KB)
- Medicines shortages and discontinuations project (PDF 712KB)
- NI Drug Tariff Intelligence (PDF 1133KB)
- Revocation of International Travel regulations (PDF 572KB)
- NI Firefighters’ Pension Scheme – Transitional Protection Remedy – Phase One – Prospective Remedy The Firefighters’ Pension Schemes (Amendment) Order (Northern Ireland) 2022) (PDF 540KB)
- The Health and Social Care Pension Schemes, Additional Voluntary Contributions and Injury Benefits (Amendment) Regulations (Northern Ireland) 2021 (PDF 453KB)
- Introduction of Statutory Regulation of the Pharmacy Technician Workforce in Northern Ireland (PDF 537KB)
- Covid Certification Service – July 2021 (PDF 851KB)